Combination therapy before surgery for early lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug combined with other treatments for people with lung cancer that can be removed by surgery. It aims to see if the treatment shrinks tumors before surgery and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have non-small cell lung cancer that can be surgically removed or was already fully removed.
- You are in good physical condition (able to do daily activities without help).
- Your major organs (like bone marrow, liver, and kidneys) are working well enough.
- You have not had certain immune-related conditions, infections, or other cancers in the past few years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
This trial tests whether giving a combination of an immunotherapy drug (adebrelimab) and chemotherapy before surgery can shrink tumors better in lung cancer that has certain genetic changes. The hope is that this pre-surgery treatment will improve outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests whether combining two drugs, adebrelimab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that blocks blood supply to tumors), before surgery can improve outcomes for people with early-stage non-small cell lung cancer. The goal is to shrink the tumor and make surgery more effective.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.